U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. News & Events
  3. FDA Meetings, Conferences and Workshops
  4. Immune Globulin Hypersensitivity Reactions: Root Causes and Mitigation; Public Workshop - 03/30/2023
  1. FDA Meetings, Conferences and Workshops

Workshop | Virtual

Event Title
Immune Globulin Hypersensitivity Reactions: Root Causes and Mitigation; Public Workshop
March 30, 2023

Scheduled
Date:
March 30, 2023
Time:
8:30 AM - 4:15 PM ET
Organized By:
Organizer

BACKGROUND:

Immune Globulins (IGs) are used extensively to treat primary and secondary antibody deficiencies, and a variety of autoimmune diseases.  The purpose of the workshop is to gain insight and to identify measures to prevent   hypersensitivity reactions associated with specific lots of Immune Globulins (IG).   The symptoms of these reactions typically include urticaria, hives, pruritis, and orofacial swelling.   Occasionally, these skin-related symptoms are accompanied by chest pain or shortness of breath.  In some patients, anaphylaxis-like events have been reported.

Although hypersensitivity is listed as a possible reaction to IG products, FDA and manufacturers have observed excessive numbers of hypersensitivity reactions for specific lots of IG.  Such lots occur episodically and unpredictably.  This phenomenon has led to voluntary market withdrawals of IG product lots and adversely affected a proportion of patient recipients.  Resulting withdrawals of product lots and quarantine of manufacturing intermediates can adversely affect IG supply. The cause of these reactions is unknown.  

TOPICS FOR DISCUSSION:

  1. Clinical presentations and epidemiology of patients with hypersensitivity reactions to specific lots of IG  
  2. Pathogenesis of Type I hypersensitivity reactions
  3. Manufacturer investigations – including plasma donor factors, potential recipient risk factors, and manufacturing and laboratory investigations of implicated plasma units and IG lots 

AGENDA:

Immune Globulin Hypersensitivity Reactions: Root Causes and Mitigation Agenda

OBJECTIVES:

The overarching workshop goals are to enhance patient safety and preserve product availability.  The objectives of the workshop are to share knowledge that will contribute to prevention of lot-specific hypersensitivity reactions, and to seek opinions from scientific experts on:

  • The most likely root cause(s) of reactions
  • Potential recipient risk factors  
  • Development of pragmatic in vitro methods to identify plasma units or products that mediate lot-specific hypersensitivity 

RECORDING:

Topic: Immune Globulin Hypersensitivity Reactions: Root Causes and Mitigation - Recordings

LOCATION:

This is a virtual webcast only event.  The link for viewing/participation will be provided within your Eventbrite confirmation upon registration.

REGISTRATION INFORMATION:

To register for this public workshop, please visit the following website: https://www.eventbrite.com/e/immune-globulin-hypersensitivity-reactions-root-causes-and-mitigation-tickets-558320711277.  Registration is free and based on space availability.  If you need special accommodations due to a disability, please contact Loni Warren Henderson or Sherri Revell no later than March 23, 2023 (subject line:  IG Hypersensitivity Workshop) at the contact information provided below.

FOR FURTHER INFORMATION CONTACT:

Loni Warren Henderson or Sherri Revell, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 1118, Silver Spring, MD 20993, or 240-402-8180, or CBERPublicEvents@fda.hhs.gov (subject line: IG Hypersensitivity Workshop)

Back to Top